Two-Drug combo targets Hard-to-Treat ovarian cancer

NCT ID NCT05071937

Recruiting now Disease control Sponsor: Alexander B Olawaiye, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether combining two oral drugs—ZEN003694 (a BET inhibitor) and talazoparib (a PARP inhibitor)—can shrink tumors in people with recurrent ovarian, fallopian tube, or primary peritoneal cancer. Participants must have already received a PARP inhibitor before. The study aims to see how many patients respond and what side effects occur.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ZEN003694 and talazoparib
What this could lead to: If successful, this combination could offer a new treatment option for people with recurrent ovarian cancer who have already tried a PARP inhibitor.
What could go wrong: This is a small, early-phase trial (33 participants) with no control group. The combination may cause side effects and might not shrink tumors as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer fallopian tube carcinoma fallopian tube neoplasm ovarian cancer ovarian carcinoma peritoneum cancer primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FALLOPIAN TUBE CANCER OVARIAN CANCER PERITONEAL CANCER

Contacts and locations

Locations

University of Pittsburgh Medical Center
RECRUITING

Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.